A Retrospective Observational Study of Safety and Effectiveness of Abemaciclib in Chinese Patients with Breast Cancer - PubMed
10 hours ago
- #treatment safety
- #real-world evidence
- #breast cancer
- Abemaciclib demonstrated a well-tolerated safety profile with adverse events mostly of grades 1-2, with neutropenia being the most common in Chinese patients with breast cancer.
- Effectiveness analysis among advanced breast cancer patients showed that 12-month real-world progression-free survival and overall survival rates varied by therapy line, being highest in first-line treatment.
- The study confirms abemaciclib's positive benefit-risk profile in real-world clinical practice, aligning with findings from prior clinical trials, and shows consistency across different patient subgroups.